Finanzen von Valneva SE (VALN)VALNValneva SE

Valneva SE (VALN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is IXIARO, accounting for 56.1% of total sales, equivalent to €54.70M. Other significant revenue streams include DUKORAL and Third party products. Understanding this composition is critical for investors evaluating how VALN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Valneva SE maintains a gross margin of 9.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -75.76%, while the net margin is -96.10%. These profitability ratios, combined with a Return on Equity (ROE) of -117.85%, provide a clear picture of how effectively VALN converts its operational activities into shareholder value.

In the context of the broader market, VALN competes directly with industry leaders such as CABA and SCTX. With a market capitalization of $676.09M, it holds a leading position in the sector. When comparing efficiency, VALN's gross margin of 9.60% stands against CABA's N/A and SCTX's N/A. Such benchmarking helps identify whether Valneva SE is trading at a premium or discount relative to its financial performance.

Valneva reported a net loss of €63.3 million in H1 2026, significantly higher than the €20.8 million loss in the prior year, indicating worsening financial health. Product sales also declined from €91 million in H1 2025 to €64 million in H1 2026 due to reduced distribution activities.